Cantor Fitzgerald Forecasts Weaker Earnings for Exagen

Exagen Inc. (NASDAQ:XGN) – Cantor Fitzgerald decreased their FY2026 earnings per share estimates for shares of Exagen in a research note issued to investors on Wednesday, November 5th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($0.90) per share for the year, down from their prior estimate of ($0.68). Cantor Fitzgerald has a “Overweight” rating and a $10.00 price target on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share.

Exagen (NASDAQ:XGN) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). Exagen had a negative net margin of 29.94% and a negative return on equity of 113.48%. The business had revenue of $17.24 million during the quarter, compared to analyst estimates of $16.90 million. Exagen has set its FY 2025 guidance at EPS.

Other analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Exagen in a research report on Wednesday, October 8th. BTIG Research increased their target price on Exagen from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. KeyCorp increased their price objective on Exagen from $12.00 to $15.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 14th. B. Riley restated a “buy” rating and set a $18.00 target price (up from $15.00) on shares of Exagen in a report on Wednesday. Finally, Craig Hallum assumed coverage on Exagen in a report on Wednesday, July 23rd. They set a “buy” rating and a $12.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Exagen presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.83.

Exagen Price Performance

NASDAQ:XGN traded down $1.00 during trading hours on Friday, hitting $9.38. 338,967 shares of the stock were exchanged, compared to its average volume of 241,349. The company has a market cap of $212.53 million, a P/E ratio of -10.20 and a beta of 1.66. The firm’s fifty day moving average price is $10.70 and its 200 day moving average price is $8.51. Exagen has a 52-week low of $2.62 and a 52-week high of $12.23. The company has a current ratio of 4.08, a quick ratio of 4.95 and a debt-to-equity ratio of 1.35.

Institutional Trading of Exagen

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in Exagen by 7.7% during the third quarter. Vanguard Group Inc. now owns 733,824 shares of the company’s stock valued at $8,065,000 after purchasing an additional 52,205 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Exagen by 320,280.0% during the third quarter. JPMorgan Chase & Co. now owns 16,019 shares of the company’s stock valued at $176,000 after buying an additional 16,014 shares during the last quarter. Huntleigh Advisors Inc. grew its holdings in shares of Exagen by 6.3% during the 3rd quarter. Huntleigh Advisors Inc. now owns 93,353 shares of the company’s stock worth $1,026,000 after purchasing an additional 5,492 shares in the last quarter. Calamos Advisors LLC raised its stake in shares of Exagen by 3.5% in the 3rd quarter. Calamos Advisors LLC now owns 78,090 shares of the company’s stock valued at $858,000 after buying an additional 2,677 shares in the last quarter. Finally, Manatuck Hill Partners LLC bought a new stake in Exagen in the second quarter valued at about $1,222,000. 75.25% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Exagen news, CEO John Aballi sold 31,787 shares of the company’s stock in a transaction that occurred on Thursday, October 16th. The stock was sold at an average price of $11.82, for a total value of $375,722.34. Following the transaction, the chief executive officer directly owned 714,427 shares of the company’s stock, valued at $8,444,527.14. This represents a 4.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 12.60% of the stock is currently owned by company insiders.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).